Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.

IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tumors expressing ≥1 of 8 predefined targets underwent leukapheresis. Endogenous T cells specific for up to 4 targets were primed and expanded in vitro. Patients received lymphodepletion (fludarabine, cyclophosphamide), followed by T-cell infusion and low-dose IL2 (Cohort 1). Patients in Cohort 2 received atezolizumab for up to 1 year (NCT02876510). Overall, 214 patients were screened, 15 received lymphodepletion (13 women, 2 men; median age, 44 years), and 14 were treated with T-cell products. IMA101 treatment was feasible and well tolerated. The most common adverse events were cytokine release syndrome (Grade 1, n = 6; Grade 2, n = 4) and expected cytopenias. No patient died during the first 100 days after T-cell therapy. No neurotoxicity was observed. No objective responses were noted. Prolonged disease stabilization was noted in three patients lasting for 13.7, 12.9, and 7.3 months. High frequencies of target-specific T cells (up to 78.7% of CD8+ cells) were detected in the blood of treated patients, persisted for >1 year, and were detectable in posttreatment tumor tissue. Individual T-cell receptors (TCR) contained in T-cell products exhibited broad variation in TCR avidity, with the majority being low avidity. High-avidity TCRs were identified in some patients' products. This study demonstrates the feasibility and tolerability of an actively personalized ACT directed to multiple defined pHLA cancer targets. Results warrant further evaluation of multi-target ACT approaches using potent high-avidity TCRs. See related Spotlight by Uslu and June, p. 865.

Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.

T cell receptor (TCR)-based immunotherapy has emerged as a promising therapeutic approach for the treatment of patients with solid cancers. Identifying peptide-human leukocyte antigen (pHLA) complexes highly presented on tumors and rarely expressed on healthy tissue in combination with high-affinity TCRs that when introduced into T cells can redirect T cells to eliminate tumor but not healthy tissue is a key requirement for safe and efficacious TCR-based therapies. To discover promising shared tumor antigens that could be targeted via TCR-based adoptive T cell therapy, we employed population-scale immunopeptidomics using quantitative mass spectrometry across ~1500 tumor and normal tissue samples. We identified an HLA-A*02:01-restricted pan-cancer epitope within the collagen type VI α-3 (COL6A3) gene that is highly presented on tumor stroma across multiple solid cancers due to a tumor-specific alternative splicing event that rarely occurs outside the tumor microenvironment. T cells expressing natural COL6A3-specific TCRs demonstrated only modest activity against cells presenting high copy numbers of COL6A3 pHLAs. One of these TCRs was affinity-enhanced, enabling transduced T cells to specifically eliminate tumors in vivo that expressed similar copy numbers of pHLAs as primary tumor specimens. The enhanced TCR variants exhibited a favorable safety profile with no detectable off-target reactivity, paving the way to initiate clinical trials using COL6A3-specific TCRs to target an array of solid tumors.

Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.

PURPOSE: Immunotherapy for hepatocellular carcinoma (HCC) shows considerable promise in improving clinical outcomes. HepaVac-101 represents a single-arm, first-in-human phase I/II multicenter cancer vaccine trial for HCC (NCT03203005). It combines multipeptide antigens (IMA970A) with the TLR7/8/RIG I agonist CV8102. IMA970A includes 5 HLA-A*24 and 7 HLA-A*02 as well as 4 HLA-DR restricted peptides selected after mass spectrometric identification in human HCC tissues or cell lines. CV8102 is an RNA-based immunostimulator inducing a balanced Th1/Th2 immune response. PATIENTS AND METHODS: A total of 82 patients with very early- to intermediate-stage HCCs were enrolled and screened for suitable HLA haplotypes and 22 put on study treatment. This consisted in a single infusion of low-dose cyclophosphamide followed by nine intradermal coadministrations of IMA970A and CV8102. Only patients with no disease relapse after standard-of-care treatments were vaccinated. The primary endpoints of the HepaVac-101 clinical trial were safety, tolerability, and antigen-specific T-cell responses. Secondary or exploratory endpoints included additional immunologic parameters and survival endpoints. RESULTS: The vaccination showed a good safety profile. Transient mild-to-moderate injection-site reactions were the most frequent IMA970A/CV8102-related side effects. Immune responses against ≥1 vaccinated HLA class I tumor-associated peptide (TAA) and ≥1 vaccinated HLA class II TAA were respectively induced in 37% and 53% of the vaccinees. CONCLUSIONS: Immunotherapy may provide a great improvement in treatment options for HCC. HepaVac-101 is a first-in-human clinical vaccine trial with multiple novel HLA class I- and class II-restricted TAAs against HCC. The results are initial evidence for the safety and immunogenicity of the vaccine. Further clinical evaluations are warranted.

UV-LED projection photolithography for high-resolution functional photonic components.

The advancement of micro- and nanostructuring techniques in optics is driven by the demand for continuous miniaturization and the high geometrical accuracy of photonic devices and integrated systems. Here, UV-LED projection photolithography is demonstrated as a simple and low-cost approach for rapid generation of two-dimensional optical micro- and nanostructures with high resolution and accuracy using standard optics only. The developed system enables the projection of structure patterns onto a substrate with 1000-fold demagnification. Photonic devices, e.g., waveguides and microring resonators, on rigid or flexible substrates with varied geometrical complexity and overall structure dimensions from the nanometer to centimeter scale were successfully prepared. In particular, high-resolution gratings with feature sizes down to 150 nm and periods as small as 400 nm were realized for the first time by this approach. Waveguides made of doped laser active materials were fabricated, and their spontaneous emission was detected. The demonstrated superior performance of the developed approach may find wide applications in photonics, plasmonics, and optical materials science, among others.

Experimental Demonstration of Surface Plasmon Polaritons Reflection and Transmission Effects.

Special integrated photonic surface structures composed of a dielectric semicircle ridge and a dielectric block placed on a metal substrate are proposed for the investigation of surface plasmon polariton (SPP) reflection and transmission effects. A fabrication method called microscope projection photolithography was employed for the preparation of the structures. Leakage radiation microscopy was applied for the excitation and observation of surface plasmon polaritons (SPPs). It was observed that SPPs exhibit a remarkable decrease in intensity when impinging onto the rectangular dielectric block. Nevertheless, the transmitted wave out of the dielectric block was always observable. The propagation behavior of both the reflected waves at two boundaries (air/dielectric and dielectric/air) and the transmitted wave inside the dielectric block were demonstrated for different SPP incident conditions. The variation of the angles of reflection and transmission with respect to the incident angle was analytically and experimentally investigated. An agreement between the calculated results and the experimental results was obtained. Our findings might allow for novel applications in sensing and analytics once the structures will be functionalized.

Femtosecond time-resolved photoemission electron microscopy operated at sample illumination from the rear side.

We present an advanced experimental setup for time-resolved photoemission electron microscopy (PEEM) with sub-20 fs resolution, which allows for normal incidence and highly local sample excitation with ultrashort laser pulses. The scheme makes use of a sample rear side illumination geometry that enables us to confine the sample illumination spot to a diameter as small as 6 µm. We demonstrate an operation mode in which the spatiotemporal dynamics following a highly local excitation of the sample is globally probed with a laser pulse illuminating the sample from the front side. Furthermore, we show that the scheme can also be operated in a time-resolved normal incidence two-photon PEEM mode with interferometric resolution, a technique providing a direct and intuitive real-time view onto the propagation of surface plasmon polaritons.

Nanofabrication of High-Resolution Periodic Structures with a Gap Size Below 100 nm by Two-Photon Polymerization.

In this paper, approaches for the realization of high-resolution periodic structures with gap sizes at sub-100 nm scale by two-photon polymerization (2PP) are presented. The impact of laser intensity on the feature sizes and surface quality is investigated. The influence of different photosensitive materials on the structure formation is compared. Based on the elliptical geometry character of the voxel, the authors present an idea to realize high-resolution structures with feature sizes less than 100 nm by controlling the laser focus position with respect to the glass substrate. This investigation covers structures fabricated respectively in the plane along and perpendicular to the major axis of voxel. The authors also provide a useful approach to manage the fabrication of proposed periodic structure with a periodic distance of 200 nm and a gap size of 65 nm.

The Interaction of Guest Molecules with Co-MOF-74: A Vis/NIR and Raman Approach.

Co-MOF-74 rod like crystals with a length of several hundred micrometers are synthesized by a solvothermal procedure and their interaction with different gases is evaluated for selective gas sensing. We show strongly anisotropic absorption behavior of the Co-MOF-74 crystals when illuminated with polarized light. The interactions of guests (CO2 , propane, propene, Ar, MeOH, H2 O) with Co-MOF-74, is studied by various spectroscopic techniques. Vis/NIR shows peak shifts of Co-MOF-74 depending on the interaction with the guest. In the visible and the NIR the maximum absorbance is shifted selectively corresponding to the intensity of the CoII -guest interaction. Even propene and propane could be distinguished at room temperature by their different interactions with Co-MOF-74. Raman spectroscopy was used to detect a modified vibrational behavior of Co-MOF-74 upon gas adsorption. We show that the adsorption of H2 O leads to a characteristic shift of the peak maxima in the Raman spectra.

Low Threshold Room Temperature Amplified Spontaneous Emission in 0D, 1D and 2D Quantum Confined Systems.

We address optical amplification properties of quantum nanoparticles of the cadmium selenide/cadmium sulfide (CdSe/CdS) material system with different dimensionality of spatial confinement. CdSe/CdS core/shell quantum dots (QDs), core/shell quantum rods (QRs) and 5 monolayer thick core/crown nanoplatelets (NPLs) at ambient temperature are considered, exhibiting 0D, 1D and 2D spatial confinement dimensionality of the electronic system, respectively. Continuous films of all these nanoparticles are synthesised, and amplified spontaneous emission (ASE) spectra are measured under femtosecond pumping at wavelengths of 400 nm and 800 nm, respectively. The lowest threshold is found for NPLs and the highest for QDs, demonstrating the influence of the rod-like and plate-like CdS structures. To emphasize this effect, ASE is demonstrated also in CdSe/CdS QRs and NPLs under nanosecond pumping at 355 nm in the same material films. The amplification has been achieved without use of any feedback structure, emphazising the efficiency of the antenna effect. The pumping threshold fluences for NPLs and QRs are observed to be similar, but no ASE is observed in QDs up to the damage threshold of the nanoparticle layers. The length variation investigation with nanosecond pumping resulted in the gain coefficients of 29 cm-1 and 37 cm-1 for QRs and NPLs, respectively.

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.

BACKGROUND: In a phase 2 study in patients with metastatic renal cell carcinoma, overall survival was associated with T-cell responses against IMA901, a vaccine consisting of ten tumour-associated peptides. In this phase 3 trial, we aimed to determine the clinical effect of adding IMA901 to sunitinib, the standard first-line treatment in metastatic renal cell carcinoma with postulated favourable immunomodulatory effects. METHODS: The IMPRINT study is an open-label, randomised, controlled, phase 3 trial done at 124 clinical sites in 11 countries. HLA-A*02-positive patients (aged ≥18 years) with treatment-naive, histologically confirmed metastatic or locally advanced (or both) clear-cell renal cell carcinoma were randomly assigned (3:2) to receive sunitinib plus up to ten intradermal vaccinations of IMA901 (4·13 mg) and granulocyte macrophage colony-stimulating factor (75 µg), with one dose of cyclophosphamide (300 mg/m2) 3 days before the first vaccination, or to receive sunitinib alone. Sunitinib (50 mg) was given orally once daily, with each cycle defined as 4 weeks on treatment followed by 2 weeks off treatment, until progression of disease as determined by the investigator, death, or withdrawal of consent. Block randomisation (block size five) was done centrally using an interactive web response system, stratified by prognostic risk, geographical region, and previous nephrectomy. Patients and investigators were not masked to treatment allocation. The primary endpoint was overall survival from randomisation until death of any cause as determined by the investigator, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01265901. FINDINGS: Between Dec 22, 2010, and Dec 15, 2012, we screened 1171 patients, of whom 339 were randomly assigned to receive sunitinib plus IMA901 (n=204) or sunitinib monotherapy (n=135). Patients had a median follow-up of 33·27 months (IQR 29·92-35·64). Median overall survival did not differ significantly between the groups (33·17 months [95% CI 27·81-41·36] in the sunitinib plus IMA901 group vs not reached [33·67-not reached] in the sunitinib monotherapy group; hazard ratio 1·34 [0·96-1·86]; p=0·087). 116 (57%) of 202 patients in the sunitinib plus IMA901 group and 62 (47%) of 132 in the sunitinib group had grade 3 or worse adverse events, the most common of which were hypertension, neutropenia, and anaemia in both groups, and mild-to-moderate transient injection-site reactions (eg, erythema, pruritus) were the most frequent IMA901-related side-effect in the sunitinib plus IMA901 group. Serious adverse events leading to death occurred in four (2%) patients (one respiratory failure and circulatory collapse [possibly related to sunitinib], one oesophageal varices haemorrhage [possibly related to sunitinib], one cardiac arrest [possibly related to sunitinib], and one myocardial infarction) and eight (6%) patients in the sunitinib group (one case each of renal failure, oesophageal varices haemorrhage, circulatory collapse, wound infection, ileus, cerebrovascular accident [possibly treatment related], and sepsis). INTERPRETATION: IMA901 did not improve overall survival when added to sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. The magnitude of immune responses needs to be improved before further development of IMA901 in this disease is indicated. FUNDING: Immatics Biotechnologies.

All-polymer arrayed waveguide grating at 850 nm: design, fabrication, and characterization.

In this Letter, a novel all-polymer arrayed waveguide grating (AWG) device with an operating wavelength around 850 nm is reported. The all-polymer AWG consists of polymer ridge waveguides fabricated on a thin poly(methyl methacrylate) foil via microscope projection photolithography. The developed device is suitable to be integrated into optical circuits, e.g., a planar polymer foil and, along with other optical integrated devices, to be used for different sensing applications. The functionality of the device is demonstrated by using a fiber Bragg grating sensor and performing strain measurements.

Cascaded-focus laser writing of low-loss waveguides in polymers.

Waveguide writing in poly (methyl methacrylate) (PMMA) with femtosecond laser radiation is presented. An adequate refractive index change is induced in the border area below the irradiated focal volume. It supports an almost symmetric fundamental mode with propagation losses down to 0.5 dB/cm, the lowest losses observed so far in this class of materials. The writing process with a cascaded focus is demonstrated to be highly reliable over a large parameter range.

Ultrafast surface plasmon-polariton logic gates and half-adder.

In this paper, we present a plasmonic model system for the realization of ultrafast all-optical NOT, AND, OR, and XOR gate operations using linear interference effects in dielectric crossed waveguide structures. The waveguides for the surface plasmon-polaritons are produced by a simple but highly accurate microscopic lithographic process and are optimized for single mode operation at an excitation laser wavelength of 800 nm. The functionality of the presented structures is demonstrated using sub-30 fs laser pulses from a mode locked titanium:sapphire laser. Using leakage radiation microscopy we show ultrafast SPP switching and logic operations of one basic structure consisting of two crossed waveguides with an additional output waveguide along the bisecting line of the input waveguides. The individual gates are realized on a footprint of 10 µm × 20 µm. Experimental investigations are supported by finite-difference time-domain simulations, where good agreement between experimental results and numerical simulations is obtained. To exploit the high precision of the fabrication method and its huge potential for realizing functional complex plasmonic circuitry we experimentally demonstrate a half-adder structure and its operation by combining and cascading several plasmonic waveguide components and logic gate elements on an area of only 10 µm × 28 µm.

The interplay between localized and propagating plasmonic excitations tracked in space and time.

In this work, the mutual coupling and coherent interaction of propagating and localized surface plasmons within a model-type plasmonic assembly is experimentally demonstrated, imaged, and analyzed. Using interferometric time-resolved photoemission electron microscopy the interplay between ultrashort surface plasmon polariton wave packets and plasmonic nanoantennas is monitored on subfemtosecond time scales. The data reveal real-time insights into dispersion and localization of electromagnetic fields as governed by the elementary modes determining the functionality of plasmonic operation units.

Laser printing of silicon nanoparticles with resonant optical electric and magnetic responses.

Silicon nanoparticles with sizes of a few hundred nanometres exhibit unique optical properties due to their strong electric and magnetic dipole responses in the visible range. Here we demonstrate a novel laser printing technique for the controlled fabrication and precise deposition of silicon nanoparticles. Using femtosecond laser pulses it is possible to vary the size of Si nanoparticles and their crystallographic phase. Si nanoparticles produced by femtosecond laser printing are initially in an amorphous phase (a-Si). They can be converted into the crystalline phase (c-Si) by irradiating them with a second femtosecond laser pulse. The resonance-scattering spectrum of c-Si nanoparticles, compared with that of a-Si nanoparticles, is blue shifted and its peak intensity is about three times higher. Resonant optical responses of dielectric nanoparticles are characterized by accumulation of electromagnetic energy in the excited modes, which can be used for the realization of nanoantennas, nanolasers and metamaterials.

Optical spectroscopy of single Si nanocylinders with magnetic and electric resonances.

Resonant electromagnetic properties of nanoparticles fabricated from high-index semiconductor or dielectric materials are very promising for the realization of novel nanoantennas and metamaterials. In this paper we study optical resonances of Si nanocylinders located on a silica substrate. Multipole analysis of the experimental scattering spectra, based on the decomposed discrete dipole approximation, confirms resonant excitation of electric and magnetic dipole modes in the Si nanocylinders. Influences of light polarization and incident angle on the scattering properties of the nanocylinders are studied. It is shown that the dependence of resonant excitation of the electric and magnetic modes in the nanocylinders on incident angle and polarization of light allows controlling and manipulating the scattered light in this system. The demonstrated properties of Si nanocylinders can be used for the realization of dielectric metasurfaces with different functional optical properties.

IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.

Despite a major improvement in the treatment of advanced kidney cancer by the recent introduction of targeted agents such as multi-kinase inhibitors, long-term benefits are still limited and a significant unmet medical need remains for this disease. Cancer immunotherapy has shown its potential by the induction of long-lasting responses in a small subset of patients, however, the unspecific immune interventions with (high dose) cytokines used so far are associated with significant side effects. Specific cancer immunotherapy may circumvent these problems by attacking tumor cells while sparing normal tissue with the use of multi-peptide vaccination being one of the most promising strategies. We here summarize the clinical and translational data from phase I and II trials investigating IMA901. Significant associations of clinical benefit with detectable T cell responses against the IMA901 peptides and encouraging survival data in treated patients has prompted the start of a randomized, controlled phase III trial in 1st line advanced RCC with survival results expected toward the end of 2015. Potential combination strategies with the recently discovered so-called checkpoint inhibitors are also discussed.

Nanostripe length dependence of plasmon-induced material deformations.

Following the impact of a single femtosecond light pulse on nickel nanostripes, material deformations-or "nanobumps"-are created. We have studied the dependence of these nanobumps on the length of nanostripes and verified the link with plasmons. More specifically, local electric currents can melt the nanostructures in the hotspots, where hydrodynamic processes give rise to nanobumps. This process is further confirmed by independently simulating local magnetic fields, since these are produced by the same local electric currents.